Methicillin-resistant Staphylococcus aureus (MRSA) has grown to become a major burden on health care systems. The cumulation of limited therapeutic options and worsened patient outcomes with persistent MRSA bacteremia has driven research in optimizing its initial management. The guidelines published by the Infectious Diseases Society of America currently recommend combination therapy for refractory MRSA bacteremia, but the utility of combining antibiotics from the start of therapy is under investigation. The alternative strategy of early use of β-lactam antibiotics in combination with vancomycin upon initial MRSA bacteremia detection has shown promise. While this concept has gained international attention, providers should give this strategy serious consideration prior to implementation. The objective of this review is to examine retrospective and prospective evidence for early combination with vancomycin and β-lactam antibiotics, as well as explore potential consequences of combination therapy.
|Journal||Antimicrobial Agents and Chemotherapy|
|State||Published - Jul 2020|
Bibliographical notePublisher Copyright:
© 2020 American Society for Microbiology. All rights reserved.
- Combination therapy
- Methicillin resistance
- Staphylococcus aureus
ASJC Scopus subject areas
- Pharmacology (medical)
- Infectious Diseases